Rosiglitazone Attenuates Age- and Diet-Associated Nonalcoholic Steatohepatitis in Male Low-Density Lipoprotein Receptor Knockout Mice
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a common complication of obesity that can progress to nonalcoholic steatohepatitis (NASH), a serious liver pathology that can advance to cirrhosis. The mechanisms responsible for NAFLD progression to NASH remain unclear. Lack of a suitable animal model that faithfully recapitulates the patho-physiology of human NASH is a major obstacle in delineating mechanisms responsible for progression of NAFLD to NASH and, thus, development of better treatment strategies. We identified and characterized a novel mouse model, middle-aged male low-density lipopro-tein receptor ( LDLR) 2/2 mice fed a high-fat diet (HFD), which developed NASH associ-ated with four of five metabolic syndrome (MS) components. In these mice, as observed in humans, liver steatosis and oxidative stress promoted NASH development. Aging exacer-bated the HFD-induced NASH such that liver steatosis, inflammation, fibrosis, oxidative stress, and liver injury markers were greatly enhanced in middle-aged versus young LDLR 2/2 mice. Although expression of genes mediating fatty acid oxidation and antioxi-dant responses were up-regulated in young LDLR 2/2 mice fed HFD, they were drastically reduced in MS mice. However, similar to recent human trials, NASH was partially attenu-ated by an insulin-sensitizing peroxisome proliferator-activated receptor-gamma (PPARc) ligand, rosiglitazone. In addition to expected improvements in MS, newly identified mech-anisms of PPARc ligand effects included stimulation of antioxidant gene expression and mitochondrial b-oxidation, and suppression of inflammation and fibrosis. LDLR-defi-ciency promoted NASH, because middle-aged C57BL/6 mice fed HFD did not develop severe inflammation and fibrosis, despite increased steatosis. Conclusion: MS mice repre-sent an ideal model to investigate NASH in the context of MS, as commonly occurs in human disease, and NASH development can be substantially attenuated by PPARc activa-tion, which enhances b-oxidation. (HEPATOLOGY 2010;52:2001-2011)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondria, Oxidants, and Aging
Balaban, R. S., Nemoto, S., & Finkel, T. (2005) · Cell · doi:10.1016/j.cell.2005.02.001 · Cited by 4,388
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 13×
“We recently identified and phenotyped an ‘‘MS mouse,’’ middle-aged (12-month-old) male low-density lipoprotein receptor (LDLR) / mice fed 3 months of a high-fat diet (HFD), which developed four of five criteria of human MS.4 These mice not only developed worse MS and diabetes than HFD-fed young (3-monthold) LDLR / mic…”
BackgroundInfluentialMolecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338 · cited 12×
“We recently identified and phenotyped an ‘‘MS mouse,’’ middle-aged (12-month-old) male low-density lipoprotein receptor (LDLR) / mice fed 3 months of a high-fat diet (HFD), which developed four of five criteria of human MS.4 These mice not only developed worse MS and diabetes than HFD-fed young (3-monthold) LDLR / mic…”
BackgroundInfluentialOrganelle isolation: functional mitochondria from mouse liver, muscle and cultured filroblasts
Frezza, C., Cipolat, S., & Scorrano, L. (2007) · Nature Protocols · doi:10.1038/nprot.2006.478 · Cited by 1,188
Chitturi, S., Abeygunasekera, S., Farrell, G. C., Holmes-Walker, J., Hui, J. M., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.30692 · Cited by 1,122
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625 · cited 1×
“Although recent vitamin E and PPARc ligand trials demonstrated positive effects, substantial unabated disease remains.(3,12,29) The present investigation demonstrates that RSG induces several hepatic mechanisms to attenuate NASH, including improved b-oxidation and mitochondrial function to decrease steatosis, suppress…”
BackgroundHodge, A. M., English, D. R., O’Dea, K., Sinclair, A. J., Makrides, M., Gibson, R. A., & Giles, G. G. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.1.189 · Cited by 287
Differential gene expression in periportal and perivenous mouse hepatocytes
Braeuning, A., Ittrich, C., Köhle, C., Hailfinger, S., Bonin, M., Buchmann, A., & Schwarz, M. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05503.x · Cited by 240
Cited by
Deng, T., Lyon, C. J., Minze, L. J., Lin, J., Zou, J., Liu, J. Z., Ren, Y., Yin, Z., Hamilton, D. J., Reardon, P. R., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.02.009 · Cited by 380
Self-citationRoles of PPARs in NAFLD: Potential therapeutic targets
Tailleux, A., Wouters, K., & Staels, B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.016 · Cited by 282
PPARs and nonalcoholic fatty liver disease
Liss, K. H. H., & Finck, B. N. (2017) · Biochimie · doi:10.1016/j.biochi.2016.11.009 · Cited by 275
Mouse models of nonalcoholic steatohepatitis in preclinical drug development
Hansen, H. H., Feigh, M., Veidal, S. S., Rigbolt, K. T., Vrang, N., & Fosgerau, K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.06.007 · Cited by 270
He, Y., Rodrigues, R. M., Wang, X., Seo, W., Ma, J., Hwang, S., Fu, Y., Trojnár, E., Mátyás, C., Zhao, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci141513 · Cited by 165
Metadata
- Authors
- Gupte, A. A., Liu, J. Z., Ren, Y., Minze, L. J., Wiles, J. R., Collins, A. R., Lyon, C. J., Pratico, D., Finegold, M. J., Wong, S. T., Webb, P., Baxter, J. D., Moore, D. D., & Hsueh, W. A.
- Venue
- Hepatology
- Published
- 2010-12
- Volume
- 52
- Issue
- 6
- Pages
- 2001-2011
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2022184946
- Cited by
- 98
- References
- 9
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rosiglitazone Attenuates Age- and Diet-Associated Nonalcoholic Steatohepatitis in Male Low-Density Lipoprotein Receptor Knockout Mice. https://app.cochat.ai/papers/10.1002/hep.23941
- The paper
- Gupte, A. A., Liu, J. Z., Ren, Y., Minze, L. J., Wiles, J. R., Collins, A. R., Lyon, C. J., Pratico, D., Finegold, M. J., Wong, S. T., Webb, P., Baxter, J. D., Moore, D. D., & Hsueh, W. A. (2010). Rosiglitazone Attenuates Age- and Diet-Associated Nonalcoholic Steatohepatitis in Male Low-Density Lipoprotein Receptor Knockout Mice. Hepatology. https://doi.org/10.1002/hep.23941
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.